Influence Mechanism Study of Paclitaxel and JAK2-STAT3 Inhibitor Nanoscale Drug Carriers on the Biological Activity of Gastric Cancer Cells
Objective To evaluate the inhibitory effect of paclitaxel(TAXOL)and JAK2-STAT3 inhibitor nanoscale drug carriers on the biological activity of gastric cancer cells.Methods Gastric cancer cell GBC-SD was selected as the research object,and PLGA(TAXOL+AZD1480)nanoparticles were constructed to determine the stability of the particles and drug release rate.The activity,proliferation,apoptosis,migration and invasion of JAK2-STAT3 signaling pathway of gastric cancer cells in the control,PLGA,TAXOL+AZD1480 and PLGA(TAXOL+AZD1480)groups were compared.Results The PLGA(TAXOL+AZD1480)nanoparticles released slowly and stably within 120 h.The levels of JAK2 and STAT3 phosphorylated protein in TAXOL+AZD1480 and PLGA groups were decreased(P＜0.05).Compared with PLGA group,TAXOL group and AZD1480 group could down-regulate the proliferation,migration,invasion and up-regulated apoptosis of gastric cancer cells,and the expression of Cyclin D1 and MMP-9 proteins were inhibited,but Cleaved-caspase-3 and Bax proteins were increased(P＜0.05).Compared with TAXOL group and AZD1480 group,TAXOL+AZD1480 group and PLGA(TAXOL+AZD1480)group further down-regulated the proliferation,migration and invasion abilities of gastric cancer cells,and up-regulated the apoptosis ability(P＜0.05).The proliferation,apoptosis,migration and invasion activities of cancer cells in TAXOL+AZD1480 group and PLGA(TAXOL+AZD1480)group were similar(P＞0.05).Conclusion The PLGA(TAXOL+AZD1480)nanoscale drug carriers co-loaded with TAXOL and AZD1480 has been successfully constructed.It has the effects of drug sustained release and gastric cancer inhibition,and its efficacy is definite,which is worthy of further clinical promotion.
gastric cancernanoparticlesnanoscale drug carrierspaclitaxelPLGATAXOLAZD1480cell activity
万方数据
维普
